Offerings - Spark Newswire

2 minute read

SAB Biotherapeutics Announces $7.9M Private Placement Of Common Stock At $1.08/Share

Today, 9:48 PM

SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for

SABS

1 minute read

Aridis Pharmaceuticals Files Prospectus Related To Resale By Certain Selling Stockholder Of Up To 7.2M Shares Of Common Stock

By Michael Horton

Today, 9:48 PM

-SEC Filing

ARDS

1 minute read

Small Biotechs Are Pulling Public Offerings, IPOs Amid ‘Current Market Conditions’

By Vandana Singh

Today, 9:48 PM

RNA biotech TransCode Therapeutics Inc (NASDAQ:RNAZ) withdrew its S-1 filing with the SEC that it made in late November. TransCode said…

PBAX

2 minute read

Free Ketamine Therapy? Laid Off Tech Workers Can Request Month Of ‘Freedom’ Program

By Lara Goldstein

Today, 9:48 PM

A considerable number of employees have been fired from their jobs at big tech firms.

AMZN

2 minute read

ADMA Biologics Announces Pricing Of Public Offering For $6M Of Common Stock

By Benzinga Newsdesk

Today, 9:48 PM

ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived

ADMA

2 minute read

X4 Pharmaceuticals Prices $65M Public Offering

By Benzinga Newsdesk

Today, 9:48 PM

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today the pricing of its

XFOR

1 minute read

Versus Systems Prices 2.1M Unit Offering For Gross Proceeds Of ~$2.1M

By Bill Haddad

Today, 9:48 PM

LOS ANGELES, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Versus Systems Inc. ("Versus" or the "Company") (NASDAQ:VS) today announced the pricing of its public offering of 2,100,000 units for gross proceeds of

1 minute read

Syndax Late Tuesday Announced it Priced ~6.8M Public Share Offering of Common Stock @$22/Share

By Charles Gross

Today, 9:48 PM

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.

SNDX

3 minute read

Reported Late Tuesday, iBio Announces Pricing Of $3.5M Underwritten Public Offering Of 3,365,385 Shares Of Common Stock At A Price Of $1.04/Share

By Benzinga Newsdesk

Today, 9:48 PM

iBio, Inc. (NYSEA: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering

IBIO

2 minute read

Reported Late Tuesday, Clearfield Announces Pricing Of Upsized $120M Public Offering Of Common Stock Of 1.2M Shares Of Common Stock At A Price Of $100/Share

By Benzinga Newsdesk

Today, 9:48 PM

Clearfield, Inc.

CLFD